What are the specifications of ruxolitinib tablets/ruxolitinib?

Ruxolitinib is a targeted therapy drug classified as a protein kinase inhibitor. It mainly inhibits the two genes JAK1 and JAK2, which play a key role in controlling the number of human blood cells. Ruxolitinib tablets are intended for oral administration. Each tablet contains 6.6 mg, 13.2 mg, 19.8 mg, 26.4 mg or 33 mg of Ruxolitinib phosphate, which is equivalent to 5 mg, 10 mg, 15 mg, 20 mg or 25 mg of ruxolitinib free base.

Ruxolitinib in ruxolitinib tablets is a Janus-activated kinase inhibitor (JAK) that can selectively inhibit JAK1 and JAK2 protein kinases. It is an oral medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with high-risk myelofibrosis, polycythemia vera who are intolerant or resistant to hydroxyurea, and steroid-refractory acute graft-versus-host disease. In 2011, based on the results of the COMFORT-I and COMFORT-II trials, the FDA approved ruxolitinib tablets for the treatment of myelofibrosis. At the time, it was the only therapy approved to treat intermediate- and high-risk myelofibrosis.

When these genes are defective, it can cause the body to abnormally produce too many blood cells. Ruxolitinib effectively reduces the production of excess blood cells by blocking signals from these defective genes. Dosing regimens are based on the patient's individual condition and blood results. This medication is only available with a doctor's prescription. Ruxolitinib tablets should not be taken with grapefruit or grapefruit juice due to possible interactions that increase ruxolitinib tablets exposure; however, patients may take it with or without other foods according to their preference.